A metabolic marker–based diagnostic model for precancerous and malignant endometrial lesions in insulin-resistant PCOS women with sonographically suspected endometrial polyps - Takeaways - MDSpire

A metabolic marker–based diagnostic model for precancerous and malignant endometrial lesions in insulin-resistant PCOS women with sonographically suspected endometrial polyps

  • By

  • Ying Yang

  • Ningning Hu

  • Weimin Fan

  • Liwen Zhang

  • He Fei

  • Jun Ye

  • Yang Gao

  • Ju Yang

  • Jiangnan Pei

  • Rujun Chen

  • July 13, 2026

Share

  • 1

    The study involved 185 PCOS-IR patients with ultrasound-detected endometrial polyps, categorized into benign, atypical hyperplasia, and endometrial carcinoma groups.

  • 2

    The endometrial neoplasia group showed significantly higher HOMA-IR, fasting plasma glucose, and fasting insulin compared to the benign group.

  • 3

    The final predictive model included age, HDL-C, free androgen index, and HOMA-IR, achieving moderate discrimination with an AUC of 0.767.

  • 4

    High sensitivity (0.913) and a specificity of 0.500 were observed in the model, indicating its potential for risk stratification.

  • 5

    The model remains hypothesis-generating and requires further external validation before clinical application due to its exploratory nature.

Original Source(s)

A metabolic marker–based diagnostic model for precancerous and malignant endometrial lesions in insulin-resistant PCOS women with sonographically suspected endometrial polyps

  • by Ying Yang, Ningning Hu, Weimin Fan, Liwen Zhang, He Fei, Jun Ye, Yang Gao, Ju Yang, Jiangnan Pei, Rujun Chen

  • July 13, 2026

Related Content

Past present and future of radiosensitization in cervical cancer

Contraceptive Progestogens and Incident Meningioma

When Should Breast Cancer Risk Scores Trigger MRI?

A JAMA Internal Medicine Viewpoint urges clinicians and health systems to verify risk-model inputs before acting on automated breast cancer screening recommendations.